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Abstract Burkitt lymphoma is an aggressive B cell malignan-
cy accounting for 1–2% of all adult lymphomas. Treatment
with dose-intensive, multi-agent chemotherapy is effective but
associated with considerable toxicity. In this observational
study, we compared real-world efficacy, toxicity, and costs of
four frequently employed treatment strategies for Burkitt
lymphoma: the Lymphome Malins B (LMB), the
Berlin-Frankfurt-Münster (BFM), the HOVON, and the
CODOX-M/IVAC regimens. We collected data from 147 adult
patients treated in eight referral centers. Following central
Key message Four different first-line treatment strategies for adult
Burkitt lymphoma were compared for real-world outcome, toxicity, and
costs in a multicenter observational study. All treatment strategies were
associated with high cure rates and were comparable in safety.
Considerable differences, however, existed in treatment duration and
costs which may guide future treatment choice.
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pathology assessment, 105 of these cases were accepted as
Burkitt lymphoma, resulting in the following treatment groups:
LMB 36 patients, BFM 19 patients, HOVON 29 patients, and
CODOX-M/IVAC 21 patients (median age 39 years, range 14–
74; mean duration of follow-up 47 months). There was no
significant difference between age, sex ratio, disease stage, or
percentage HIV-positive patients between the treatment groups.
Five-year progression-free survival (69%, p = 0.966) and 5-
year overall survival (69%, p = 0.981) were comparable for
all treatment groups. Treatment-related toxicity was also com-
parable with only hepatotoxicity seen more frequently in the
CODOX/M-IVAC group (p = 0.004). Costs were determined
by the number of rituximab gifts and the number of inpatients
days. Overall, CODOX-M/IVAC had the most beneficial pro-
file with regards to costs, treatment duration, and percentage of
patients completing planned treatment. We conclude that the
four treatment protocols for Burkitt lymphoma yield nearly
identical results with regards to efficacy and safety but differ
in treatment duration and costs. These differences may help
guide future choice of treatment.
Keywords Burkitt lymphoma .Drug therapy .Survival .Cost
analysis
Introduction
Sporadic Burkitt lymphoma (BL) is a rare and highly aggres-
sive B cell malignancy, accounting for 1–2% of all adult lym-
phomas in Western Europe and North America. In the adult
population, BL most often affects young to middle-aged pa-
tients with a median age at diagnosis of 35 years [1]. Patients
often present with bulky extranodal disease, bone marrow
infiltration, and central nervous system involvement [2, 3].
Because of rapid tumor growth, prompt diagnosis and start
of treatment are important to optimize outcome [4]. Current
treatment strategies for adults have often been adapted from
pediatric protocols [2, 3]. All of these protocols aim to deliver
dose-intensive, multi-agent chemotherapy with minimization
of treatment delays, and maintenance of serum drug concen-
trations. Examples are the French Lymphome Malins B
(LMB) regimen developed by the Société Française
d’Oncologie Pédiatrique [5, 6], the German Berlin-
Frankfurt-Münster (BFM) regimen developed by the
German Multicenter Study Group for Adult ALL (GMALL)
[7], the regimen of the Dutch-Belgian Cooperative Trial
Group for Hematology Oncology (HOVON) regimen [8],
and the CODOX-M/IVAC regimen [9]. The complete re-
sponse (CR) rates achieved with these regimens range be-
tween 72 and 89% [5–11].
Consensus on the optimal first line treatment for adult BL is
still lacking. The low incidence of BL has thus far precluded
direct comparison between treatment regimens in a
randomized prospective clinical trial. Retrospective compari-
son of published clinical series is hampered by different pa-
tient selection criteria and changing histopathological defini-
tions for aggressive B cell lymphoma including BL in succes-
sive WHO lymphoma classifications.
In the Netherlands, the LMB, BFM, HOVON, and
CODOX-M/IVAC regimens are all in active use with treat-
ment center preference based on historic and regional associ-
ations. Each of these regimens consists of a backbone of three
to six courses of high-dose chemotherapy. The regimens differ
in inclusion of maintenance therapy and autologous stem cell
transplantation (SCT) as part of first line treatment, as well as
agents used and dosages.
To support a rational choice for a standardized treatment of
adult BL, we performed a retrospective observational analysis
of real-world efficacy, toxicity, and costs of these four treat-
ment protocols as used in daily clinical practice. In view of the
evolving BL definitions over time, a central pathology assess-
ment was included to guarantee meaningful comparisons.
Patients and methods
Patient selection and clinical data collection
All patients treated between 1995 and 2012 with any of the
four treatment protocols under study in seven university med-
ical centers and one non-academic tertiary referral hospital in
the Netherlands were included in this study. Patients with prior
first line treatment other than a maximum of three (R-) CHOP
(-like) courses were excluded. Clinical data were collected
from the hospital records using a standardized case report
form. Adverse events were scored according to the Common
Terminology Criteria for Adverse Events (CTCAE), Version
4.0. Specifically, infectious disease was defined as infections
requiring intravenous antibiotic, antifungal, or antiviral inter-
vention, or requiring radiologic or operative intervention;
nephrotoxicity was defined as reduction of glomerular filtra-
tion rate to < 25% or creatinine increase > 3× baseline; hepa-
totoxicity was defined as elevation of transaminases > 5.0×
upper normal level. Numbers of transfusions were extracted
from the local blood bank databases. Treatment response was
based on the original radiology reports (CTor PET-CTaccord-
ing to local practice). All treatment centers used the (revised)
Cheson response criteria for response evaluation from 1999
onwards [12, 13]. Risk scores reported were the International
Prognostic Index (IPI) score [12] and the Mead 2002 BL risk
score [9].
Central pathology assessment
Patients treated with the four treatment regimens under study
were originally diagnosed with Burkitt lymphoma, small non-
256 Ann Hematol (2018) 97:255–266
cleaved cell lymphoma, atypical Burkitt lymphoma, Burkitt-
like lymphoma, B cell lymphoma with features intermediate
between Burkitt lymphoma and diffuse large B cell lymphoma
(BLU), Burkitt leukemia, mature B cell leukemia, or L3-
leukemia according to the WHO lymphoma classification
used at the time of diagnosis. Central pathology assessment
was performed by two expert hematopathologists in two
stages (D.d.J., P.M.K.). First, original pathology reports, in-
cluding consult reports at the time of diagnosis, were
reviewed. A case was accepted as BL if the following criteria
were met: small- or medium-sized cells with monotonous
morphology, proliferative index (MIB1) > 95%, and
immunophenotype consistent with BL with BCL-2 staining
negative or weak and CD10 and/or BCL-6 staining positive.
A demonstrable MYC-translocation by cytogenetic testing or
fluorescence in situ hybridization was considered supportive
but not required for selection. Second, in those cases where
the available pathology reports were insufficient or incom-
plete, complete formal review was performed, including addi-
tional BCL-2, CD10, and/or BCL-6 staining if not previously
done. All cases not meeting the listed BL criteria were exclud-
ed from this study.
Treatment regimens
Details on the treatment regimens included in this study are
summarized in Table 1. All treatment regimens included ritux-
imab from 2003 to 2004 onwards. Additional information can
be found in the supplemental treatment regimen information.
Statistical analyses
Baseline characteristics between the different treatment
groups were compared using the χ2 test or Fisher’s exact test
for categorical data and the Kruskal-Wallis test for numerical
data. Overall survival (OS) and progression-free survival
(PFS) were calculated from start of the studied treatment reg-
imen on an intention-to-treat basis and defined as the time to
death from any cause (OS), and time to diagnosis of RD or
relapse or death from any cause (whichever came first) (PFS).
Survival of patients was censored at 5 years from the start of
the studied treatment regimen or at the date of last contact,
whichever came first. The Kaplan-Meier method was used to
estimate OS and PFS, and to calculate 95% confidence inter-
vals (CI). The log-rank test was used to compare survival
between subgroups. Treatment-related mortality was calculat-
ed in a competing risks model in which lymphoma-related
mortality was considered as a competing event. The cumula-
tive incidence of relapse (CIR) was calculated in a competing
risks model, considering non-relapse mortality as competing
event. End of treatment was taken as starting time and patients
with refractory disease were excluded from the analysis.
Gray’s test was used to compare CIR between groups.
Hazard ratios (HR) were calculated using univariate Cox re-
gression models. Analyses were performed using SPSS, ver-
sion 20, and R, version 3.3.0, with libraries Bcmprsk^ and
Bprodlim.^ All reported p values are two-sided with a signif-
icance level of α = 0.05.
Cost assessment
For each treatment regimen costs for medication use, erythro-
cyte and platelet transfusions, inpatients days and autologous
graft collection (if applicable) were calculated, for an
Baverage^ patient based on the following assumptions: < 40
old, body surface area of 2 m2, weight of 75 kg, high risk BL
without CNS involvement, no dose reductions, administration
of the median number of rituximab gifts and the mean number
of blood product transfusions, and hospital admission for the
mean number of days as reported for that treatment regimen.
Costs of supportive medication and outpatient evaluations
were not taken into account but were assumed to be compa-
rable between all regimens. All costs are reported in Euro and
indexed to the year 2015 using the Dutch consumer price
index as published on the CBS Statistics Netherlands website
[14]. Sources used were the knowledge database of the Royal
Dutch Pharmacists Association (z-index) [15] per December
2015 (costs for carmustine and vindesine were obtained from
the Leiden University Medical Center Pharmacy), the Dutch
guideline for economic evaluations [16], and previous pub-
lished studies [17–19].
Results
Patient characteristics and chemotherapy regimens
A total of 147 adolescent and adult patients (14–74 years)
treated for BL with the LMB, the BFM, the HOVON, or the
CODOX-M/IVAC regimen between 1995 and 2012 were
identified (Fig. 1). Of these, 91 cases fulfilled the criteria for
BL in the first phase of the pathology assessment and 14
additional cases after complete assessment resulting in a total
of 105 confirmed BL cases. Twenty-six cases were rejected as
non-BL. Sixteen cases were considered unreviewable.
Patient characteristics and chemotherapy regimens
Baseline patient characteristics are listed in Table 2. Thirty-six
patients were treated with the LMB regimen, 19with the BFM
regimen, 29 with the HOVON regimen, and 21 with the
CODOX-M/IVAC regimen. Of the LMB patients, 11 received
the low-intermediate risk schedule (31%). Of the CODOX-M/
IVAC patients, five received the low risk schedule consisting
of three CODOX-M courses (24%). Rituximab was included
in the treatment regimen of 64% (LMB) to 100% (CODOX-
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M/IVAC) of patients. The treatment groups were similar in
most characteristics, with the following exceptions. The
HOVON group contained fewer patients with central nervous
system (CNS) involvement (p = 0.065), no patients with leu-
kemic BL (n.s.), and fewer patients with high WHO scores
(p = 0.002), resulting in slightly better overall IPI scores
(p = 0.031). The BFM group contained fewer patients with
≥ 2 extranodal sites (p = 0.037). Lastly, the LMB and
HOVON groups had fewer patients treated with rituximab
(p = 0.003) than the BFM and CODOX-M/IVAC groups.
Since the latter regimens were introduced more recently in
the Netherlands, they had a higher percentage of patients in-
cluded after 2003–2004.
Seventy-five patients (71%) completed the planned treat-
ment regimen without treatment modifications. Five patients
switched to palliative therapy due to progressive disease (two
LMB, one BFM, and two HOVON). Twenty patients
switched to more intensive therapy or received additional che-
motherapy courses due to insufficient response or heightened
risk as perceived by the treating physician (11 LMB, 2 BFM, 6
HOVON, and 1 CODOX-M/IVAC). Three patients received
fewer courses than planned or switched to less intensive ther-
apies due to toxicity or comorbidity (two LMB, one
HOVON). Two patients died early during treatment (one
LMB, one CODOX-M/IVAC). For the different treatment reg-
imens, the percentage of patients completing planned treat-
ment modifications was respectively 56% for LMB, 84% for
BFM, 69% for HOVON, and 91% for CODOX-M/IVAC
(p = 0.020).
Response rates and survival
Clinical outcomes related to chemotherapy regimens are
shown in Table 3. Median follow-up of all patients was
47 months (range 4–172 months). Duration of follow-up
was variable between treatment groups (p = 0.002) due to
CODOX-M/IVAC having been introduced more recently
(maximum follow-up duration 75 months). To minimize po-
tential effects of late non-relapse mortality in the other three
treatment groups (maximum follow-up duration 147–
172 months), survival was censored at 5 years.
Of the 67 patients who achieved CR (Table 3), four
patients relapsed (6%) and eventually died of disease pro-
gression. Two of these patients had been treated with the
LMB regimen and two with the HOVON regimen. One
patient in CR received intensification therapy including
an allogeneic SCT directly following the treatment regi-
men because of extensive CNS involvement at presenta-
tion but died due to treatment-related complications. All
other patients with initial complete responses were alive
at the end of follow-up (93%).
There were no significant differences between the treat-
ment regimens with respect to progression-free survival
and overall survival, response rates, and relapse rates
(Fig. 2 and Table 3). Because advanced patient age has
been associated with poorer outcome in BL and the differ-
ent treatment regiments might impact older patients differ-
ently, we stratified for patient age < 40 years versus patient
age ≥ 40 years. No significantly different survival rates
emerged between the treatment regimens for the different
age groups (p = 0.991 for 5-year OS of patients < 40 years,
p = 0.845 for 5-year OS of patients ≥ 40 years). Likewise,
no different survival rates were detected following stratifi-
cation for low (0–2) versus high (3–5) IPI scores (p = 0.885
for 5-year OS of patients with low IPI scores, p = 0.841 for
5-year OS of patients with high IPI scores). We could make
no calculations for low versus high BL scores due to insuf-
ficient events in the low BL score group. Prognostic factors
and survival rates for the various risk groups are listed in
the Supplementary Material.
Toxicity and treatment-related mortality
Transfusion requirements and CTCAE grade III–IV infectious
disease, nephrotoxicity, or hepatotoxicity occurred in all four
treatment groups. The affected percentage of patients was as
follows for the LMB, BFM, HOVON, and CODOX-M/IVAC
regimens, respectively: transfusion requirement 97, 95, 88,
and 100% (p = 0.386); infectious disease 71, 63, 52, and
86% (p = 0.095); nephrotoxicity 11, 5.3, 4, and 7%
(p = 0.672); hepatotoxicity 29, 26, 4, and 53% (p = 0.004).
No significant difference in transfusion requirement or the
Fig. 1 Central pathology assessment flow chart
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occurrence of these toxicities was detected between patients <
40 years and patients ≥ 40 years.
Treatment-related deaths were rare: two patients died due
to sepsis during the first course of chemotherapy) (one
CODOX-M/IVAC, one LMB), five patients died from
treatment-related complications from intensification therapy,
including the three patients who received an allogeneic SCT.
Two patients died during follow-up from unknown causes.
Treatment-related mortality corrected for competing events
was 5% (95% CI, 1–9%) at 1 year and 6% (95% CI, 1–
10%) at 2 years after start of treatment.
Treatment of partial response, refractory disease,
and disease relapse
Treatment strategies for partial response, refractory disease,
and disease relapse were highly variable and dependent on
patient condition, extent of disease, and earlier treatment. Of
the 14 patients with PR, 9 patients received additional therapy.
Four of these patients received local radiation therapy only,
none of whom relapsed. The other five patients received ad-
ditional chemotherapy, followed in three cases by autologous
SCT. All of these patients achieved prolonged remissions. Of
Table 2 Patient characteristics per treatment regimen
Treatment regimen LMB BFM HOVONa CODOX-M/IVAC All P value
N 36 19 29 21 105
Age median (range) 35 (14–74) 40 (19–57) 39 (15–57) 39 (17–62) 39 (14–74) 0.784
< 40 years 22 (61%) 9 (47%) 15 (52%) 11 (52%) 57 (54%)
≥ 40 years 14 (39%) 10 (53%) 14 (48%) 10 (48%) 46 (46%)
Sex 0.098
Male 27 (75%) 9 (47%) 23 (79%) 14 (67%) 73 (70%)
Female 9 (25%) 10 (53%) 6 (21%) 7 (33%) 32 (30%)
Ann Arbor stage 0.695
I–II 9 (25%) 3 (16%) 9 (31%) 5 (24%) 26 (25%)
III–IV 27 (75%) 16 (84%) 20 (69%) 16 (76%) 79 (75%)
Extranodal involvement
Bone marrow 12 (34%) 7 (37%) 7 (24%) 9 (43%) 35 (34%) 0.559
Central nervous system 8 (22%) 5 (26%) 3 (10%) 9 (43%) 25 (24%) 0.065
Gastrointestinal tract 13 (36%) 10 (53%) 14 (48%) 6 (29%) 43 (41%) 0.335
≥ 2 sites 19 (54%) 2 (14%) 8 (29%) 9 (43%) 38 (39%) 0.037
LDH > upper normal level 28 (80%) 14 (78%) 17 (63%) 16 (76%) 75 (74%) 0.464
WHO performance scoreb 0.002
0–1 20 (56%) 6 (55%) 22 (92%) 19 (73%) 67 (73%)
> 1 16 (44%) 5 (45%) 2 (8%) 2 (27%) 25 (27%)
Bulky disease ≥ 10 cm 9 (27%) 2 (11%) 6 (21%) 7 (33%) 24 (24%) 0.371
Peripheral blood blasts ≥ 30% 1 (3%) 2 (2%) 0 2 (10%) 5 (5%) 0.224
IPI-score c 0.031
0–2 11 (31%) 6 (38%) 17 (65%) 12 (57%) 46 (47%)
3–5 25 (69%) 10 (62%) 9 (35%) 9 (43%) 53 (53%)
BL-risk scorec 0.874
Low 4 (11%) 1 (6%) 3 (12%) 3 (14%) 11 (11%)
High 32 (89%) 16 (94%) 23 (89%) 18 (86%) 89 (89%)
HIV positivity 3 (9%) 1 (6%) 6 (21%) 3 (16%) 13 (13%) 0.384
Rituximab in regimen 23 (64%) 18 (95%) 23 (79%) 21 (100%) 85 (81%) 0.003
Lymphoma treatment prior to initiation of studied regimend 3 (8%) 5 (26%) 3 (10%) 1 (5%) 12 (11%) 0.141
LDH lactate dehydrogenase, HIV human immunodeficiency virus
a Seven of these patients were included in the original prospective HOVON 27 study [8]
bWHO performance score data missing for 13 patients, resulting in incalculable IPI-scores for 6 patients
c International Prognostic Index (IPI) score: age > 60 years, Ann Arbor stage III/IV disease, elevated serum lactate dehydrogenase (LDH), WHO
performance score > 1, > 1 extranodal site (1 point for each) [20]; BL risk score: Ann Arbor stage III/IV disease, elevated serum LDH, WHO
performance score > 1, and bulky disease (1 point for each) [9]
dMaximum of 3 (R-) CHOP (-like) courses
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the untreated patients, two relapsed and one died of unknown
causes. The other two patients remained in remission. Overall,
5-year OS of PR patients was 79% (median follow up
51 months, range 18–172 months) as opposed to 92% 5-year
OS of CR patients. Of the 22 patients with RD, 21 died due to
disease progression, one patient achieved remission after an
intensive chemotherapy schedule.
All patients who relapsed eventually died, either due to
disease progression or to complications of therapy. Median
duration of disease-free survival in patients who relapsed
was 3.5 months to first relapse. All relapses but one occurred
within the first 9 months. In total, 23 of the 31 patients that
were no longer alive at the end of follow-up died due to pro-
gressive disease.
Duration and costs of treatment
For all patients who completed high-risk protocol treatment
without treatment schedule modifications, we calculated total
duration of treatment and number of inpatient days as well as
treatment costs (Table 4). The CODOX-M/IVAC regimen had
the overall shortest duration of treatment (95 days versus 149–
Table 3 Outcomes per treatment regimen
Treatment regimen LMB BFM HOVON CODOX-M/IVAC All P
value
N 36 19 29 21 105
Response rates
Complete response 22 (65%) 10 (53%) 20 (69%) 15 (75%) 67 (66%) 0.501
Partial response 5 (15%) 4 (21%) 3 (10%) 2 (10%) 14 (14%) 0.705
Refractory disease 7 (21%) 5 (26%) 6 (21%) 3 (15%) 21 (21%) 0.858
Not evaluable 2 (6%) 0 0 1 (5%) 3 (3%)
Relapse rates
Relapse (at 1 year after
end of treatment,
corrected for competing
events)
7% (95% CI
0–17%)
0% (95% CI 0–0%) 9% (95% CI
0–21%)
12% (95% CI
0–28%)
7% (95% CI
2–13%)
0.612
5-year survival rates
Progression-free survival 67% (95% CI
53–80%)
74% (95% CI
57–91%)
68% (95% CI
53–83%)
71% (95% CI
54–88%)
69% (95% CI
60–78%)
0.966
Overall survival 66% (95% CI
53–80%)
74% (95% CI
54–93%)
71% (95% CI
54–88%)
70% (95% CI
50–90%)
69% (95% CI
60–78%)
0.981
Fig. 2 a Progression-free survival of BL patients treated with the LMB,
BFM,HOVON, or CODOX-M/IVAC regimens. bOverall survival of BL
patients treated with the LMB, BFM, HOVON, or CODOX-M/IVAC
regimens. LMB, black line; BFM, red line; HOVON, green line; and
CODOX-M/IVAC, blue line
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231 days for the other regimens). The HOVON regimen had
the lowest number of inpatient days (63 days versus 93–
134 days for the other regimens). The low risk variants of
CODOX-M/IVAC and LMB (not shown in table) had median
treatment duration of 78 days (range 68–85) and 102 days
(range 90–159) and median inpatient treatment of 58 days
(range 45–62) and 51 days (range 38–66), respectively.
For treatment costs, the number of inpatient days and
the number of rituximab gifts were the most important
determinants. The number of rituximab gifts was not de-
fined in the original treatment protocols. In practice, most
treatment centers chose to administer 1–2 rituximab gifts
per chemotherapy course in varying schedules. In the
treatment regimens evaluated in this study, the number
of rituximab gifts varied from four (LMB regimen) to
eight (BFM regimen). The HOVON regimen was associ-
ated with the lowest total costs mainly due to the lowest
number of inpatient days (91,394 €). The LMB regimen
was associated with the lowest drug costs mainly due to
the lowest number of rituximab administrations (13,222 €
drug cost). The BFM protocol carried the highest costs as
it comprised both the highest number of inpatient days as
well as the highest cumulative rituximab dose (141,877
€).
Discussion
In the absence of a standard first line treatment of adult BL, we
studied Breal-world^ efficacy, toxicity, and costs of four BL
regimens frequently used in the Netherlands: LMB, BFM,
HOVON, and CODOX-M/IVAC. Our aim was to support an
evidence-based choice for a first line BL treatment regimen.
Central pathology assessment was performed to ensure inclu-
sion only of BL cases selected according to 2008 WHO clas-
sification criteria. These criteria remain essentially unchanged
in the upcoming WHO 2016 classification [21], so that our
study population remains a good approximation also of the
WHO 2016 BL population.
Having validated the diagnosis, we found patient selection
in the four treatment groups to be mostly similar in terms of
age, known risk factors, and composite indices. The HOVON
treatment group contained relatively fewer high-risk patients
because patients with CNS disease and leukemic BL were
excluded from the HOVON27 trial, which included patients
up to 2003 [8], and were also not routinely treated with this
regimen in the years that followed. In the HOVON and LMB
treatment groups, fewer patients received rituximab as a
higher percentage of patients started treatment prior to
2003–2004. Despite these differences, we found PFS and
OS rates to be comparable between the four treatment regi-
mens. Addition of rituximab did not significantly affect OS
but did show a possible trend toward improved survival espe-
cially in the older patient groups (Supplemental Material on
prognostic factors). Our data do not allow us to draw conclu-
sions on the optimal number of rituximab gifts.
Next to efficacy, the toxicity spectrum could serve as an
important parameter for optimal treatment choice. Overall, the
treatment regimens seem to be comparably safe. Only hepa-
totoxicity was significantly different between the treatment
regimens and highest for the CODOX-M/IVAC regimen.
The relevance of this finding is unclear as dose adjustment
Table 4 Duration and cost of treatment per treatment regimen
Treatment regimen LMBa BFM HOVONb CODOX-M/IVAC P value
N 13 16 18 15
Median number of treatment days (range)
Duration of treatment according to protocol 217 168 105 84
Observed duration of treatment 231 (193–319) 171 (146–226) 149 (121–215) 95 (80–155) < 0.001
Planned number of inpatient days according to protocol 129 147 66 84
Observed number of inpatient days 102 (70–148) 134 (100–169) 63 (53–109) 93 (75–130) < 0.001
Treatment costs in €
Medication costs excluding rituximab 5940 7702 11,272 9323
Rituximab 7282 14,564 9103 10,923
Blood product transfusions 14,964 5349 4838 16,204
Diagnostic procedures 18,627 27,941 13,971 18,627
Inpatient days 64,063 86,320 46,959 55,991
Autologous graft mobilization and harvestc – – 5251 –
Total costs in € 110,876 141,877 91,394 111,068
aData shown for high risk protocol
b Including 3× RiCHOP
cCosts for daycare, medication, laboratory activities, and apheresis procedure related to mobilization/harvesting of autologous graft
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for hepatotoxicity was reported for only one patient during
first line treatment (LMB regimen). Since our analysis was
limited to toxicities that could be quantifiably extracted from
patient records, mucositis was not evaluated despite being a
frequent cause of morbidity in patients undergoing intensive
chemotherapy. In prospective studies (Table 5), incidence of
mucositis was reported as 12–14% for LMB [6], 29% for
BFM [10], 39% for HOVON [8], and 50% for CODOX-M/
IVAC [9]. While these data imply that the CODOX-M/IVAC
regimen may be more strongly associated with mucositis than
the other treatment regimens, this did not reflect in a dimin-
ished percentage of patients completing treatment.
As the final important parameter to guide medical decision-
making, we evaluated the actual costs of the various treatment
regimens and the treatment durations. Treatment duration is an
important determinant from a comprehensive health econom-
ics point of view as it affects the time period a patient is
impaired at work and at home. Dominant drivers of treatment
cost were length of in-hospital stay (€ 640 per day) and the
cumulative rituximab dose (€ 1821 per gift) for medication
costs. The HOVON regimen was associated with the shortest
in-hospital stay and the lowest medication costs. CODOX-M/
IVACwas associated with the shortest total treatment duration
and the second shortest duration of in-hospital stay and med-
ication costs. Medication costs for all regimens are likely to
decrease in the future as biosimilars of rituximab become
available.
With efficacy and safety comparable between the four
treatment regimens and health economics favoring the
HOVON and CODOX-M/IVAC regimens, we weighed the
advantages and disadvantages of these two regimens with
regard to the choice for a standard first line BL therapy.
Although the HOVON treatment group contained less high
risk patients, the CODOX-M/IVAC regimen performed equal-
ly well and was completed by a significantly higher percent-
age of patients without significant treatment modifications.
The CODOX-M/IVAC regimen has the further advantage of
a low risk protocol variant with reduced doses of alkylating
agents. Since these drugs are most commonly associated with
chemotherapy-induced infertility, this is of relevance for the
low risk population that mostly comprises young patients
[30]. Based on these considerations, the CODOX-M/IVAC
regimen seems the most rational choice for a standard first
line BL therapy.
There are limitations to our study due to its retrospective
observational nature. One important aspect pertains to possi-
ble treatment center-related differences that might affect out-
come. The LMB-, HOVON-, and CODOX-M/IVAC regi-
mens were each practiced in two or three hospitals lessening
the impact of center-specific policies, but the BFM regimen
was practiced in one center only. The survival rates we found
are nevertheless comparable to those published in prospective
studies of the individual treatment regimens and a population-Ta
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based study comparing BFM, CODOX/M-IVAC, hyper-
CVAD, and CHOP/CHOEP regimens (Table 5), externally
validating our results. Another limitation results from the
changing standards for response evaluation from 1995 to
2012, initially involving CT and later PET-CT imaging. In
our study, two patients with PR did not receive intensification
therapy but nevertheless remained in remission and may in
fact have had a (unconfirmed) CR. Unfortunately, we could
not perform a central radiology review, but even with the
current standard of care, response evaluation in BL is known
to be difficult. In a study of 27 BL patients with post-treatment
PET-CT, positive predictive value was only 20% (negative
predictive value was 100%) [31]. A study in pediatric
Burkitt patients likewise showed a tendency for false positives
due to acute inflammation and tumor necrosis [32]. In our
study, in one PR patient, an extirpation was performed of a
single residual mass that remained PET-positive despite inten-
sification therapy, revealing an absence of vital BL tissue. This
was not, however, routinely done.We believe in selected cases
it may be prudent to strive for pathological confirmation of
positive PET/CT results following end of treatment to avoid
unnecessary intensification.
An issue highlighted by our study, is the current lack of
effective treatment for refractory or relapsed patients. Of
the 22 patients in our study that did not have a complete or
partial response, 21 died, as well as all patients that re-
lapsed. Escalation to autologous SCT is the best document-
ed treatment option [33, 34]. A 2013 study from the Center
for International Blood and Marrow Transplant Research
reported on 241 patients receiving an autologous or allo-
geneic SCT for BL in second or subsequent CR [34]. The
5-year OS was shown to be 31% following autologous
SCT and 20% following allogeneic SCT. Patients not in
CR at the time of transplant had 5-year OS of 22 and
12%, respectively. In our patient cohort, three patients re-
ceived allogeneic SCT as intensification therapy or follow-
ing relapse but all patients died due to treatment-related
complications. Autologous SCT did seem to be effective,
but only for patients with chemosensitive disease and
would be our treatment of choice for patients with PR or
relapsed BL. Patients with refractory BL may be better
served with novel therapies targeting contributing path-
ways in an experimental trial setting.
Recently, DA-EPOCH-R was proposed as a novel,
highly promising first line treatment regimen [35]. With
this dose-adjusted low intensity regimen, 87% freedom of
disease progression was reported in 77 patients at a me-
dian follow-up of 25 months with relatively limited side
effects [36]. Since this treatment can be administered in
the outpatient setting, it is attractive from a health eco-
nomics point of view. Based on the advantages with re-
spect to cost and treatment duration, our data have led to
the choice of the CODOX-M/IVAC regimen as the
standard arm in the multinational randomized prospective
HOVON127 trial that is designed to assess the possible
superiority of DA-EPOCH-R (EU Clinical Trials register,
EudraCT 2013-004394-27). Also, our data have led at
least two treatment centers in the Netherlands to adopt
CODOX-M/IVAC as BL treatment of choice.
In summary, our study demonstrates high cure rates for BL
in a real-world setting. Given the lack of major differences in
outcome and toxicity, health economic aspects may guide the
choice of treatment.
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